DOCSLIB.ORG

Advisory Committee Briefing Materials: Available for Public Release

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advisory Committee Briefing Materials: Available for Public Release Omadacycline Paratek Pharmaceuticals Antimicrobial Drugs Advisory Committee (AMDAC) Briefing Book 01-July-2018 Omadacycline p-Toluenesulfonate Tablets and Injection For the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP) Briefing Document for: Antimicrobial Drugs Advisory Committee (AMDAC) Meeting Date: 08-Aug-2018 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE Page 1 of 124 Omadacycline Paratek Pharmaceuticals Antimicrobial Drugs Advisory Committee (AMDAC) Briefing Book 01-July-2018 TABLE OF CONTENTS TABLE OF CONTENTS .................................................................................................................2 LIST OF TABLES ...........................................................................................................................4 LIST OF FIGURES .........................................................................................................................7 LIST OF ABBREVIATIONS ..........................................................................................................8 1 INTRODUCTION ..................................................................................................................11 1.1 Unmet Need .......................................................................................................................11 1.1.1 Acute Bacterial Skin and Skin Structure Infections ....................................................12 1.1.2 Community-Acquired Bacterial Pneumonia ................................................................13 1.2 Pharmacokinetics ...............................................................................................................14 1.2.1 Distribution, Metabolism, Excretion............................................................................16 1.2.2 Effect of Hepatic and Renal Dysfunction on Pharmacokinetics ..................................16 1.2.3 Effect of Age and Gender on Pharmacokinetics ..........................................................17 1.2.4 Effect of Food on Oral Absorption ..............................................................................17 1.2.5 Drug-Drug and Other Interactions ...............................................................................17 1.3 Microbiology......................................................................................................................18 1.4 Pharmacokinetics/Pharmacodynamics ...............................................................................19 1.4.1 Population Pharmacokinetics .......................................................................................19 1.4.2 Pharmacokinetics-Pharmacodynamics and Dose Justification ....................................19 1.5 Nonclinical Studies ............................................................................................................23 1.6 Clinical Development Program ..........................................................................................23 2 EFFICACY IN ABSSSI .........................................................................................................24 2.1 Study Designs ....................................................................................................................24 2.1.1 Selection of Patients .....................................................................................................26 2.1.1.1 OASIS-1 (iv Followed by Oral) .............................................................................26 2.1.1.2 OASIS-2 (Oral Only) .............................................................................................27 2.2 Efficacy Analysis ...............................................................................................................27 2.3 Study Populations in the Pivotal Phase 3 Studies in ABSSSI ...........................................28 2.4 Efficacy Results in the Pivotal Phase 3 ABSSSI Studies ..................................................28 2.4.1 Primary Efficacy Analysis ...........................................................................................28 2.4.2 Secondary and Additional Analyses ............................................................................30 2.4.2.1 Investigator Assessment of Clinical Response ......................................................30 2.4.2.2 Clinical Response in Microbiologic Populations ...................................................31 2.4.2.3 Clinical Response by Pathogen ..............................................................................32 2.4.2.4 Microbiological Outcomes.....................................................................................34 2.5 Subpopulation Analyses.....................................................................................................35 2.6 Efficacy Conclusions in ABSSSI.......................................................................................36 3 EFFICACY IN CABP ............................................................................................................37 3.1 Study Design ......................................................................................................................37 3.1.1 Selection of Patients .....................................................................................................38 Page 2 of 124 Omadacycline Paratek Pharmaceuticals Antimicrobial Drugs Advisory Committee (AMDAC) Briefing Book 01-July-2018 3.1.1.1 Key Inclusion Criteria ............................................................................................38 3.1.1.2 Key Exclusion Criteria ...........................................................................................39 3.2 Efficacy Analysis ...............................................................................................................40 3.3 Study Population ................................................................................................................42 3.4 Microbiology......................................................................................................................46 3.5 Efficacy Results in the Pivotal Phase 3 Study in CABP ....................................................46 3.5.1 Primary Efficacy Analysis ...........................................................................................46 3.5.2 Secondary and Additional Analyses ............................................................................47 3.5.2.1 Investigator Assessment of Clinical Response ......................................................47 3.5.2.2 Clinical Response by Pathogen ..............................................................................49 3.5.2.3 Microbiological Outcomes.....................................................................................53 3.5.2.4 Clinical Response in Microbiologic Populations ...................................................54 3.5.2.5 CABP Signs and Symptoms ..................................................................................56 3.5.2.6 Subgroup Analyses ................................................................................................58 3.6 Efficacy Conclusions in the Pivotal Phase 3 Study in CABP ............................................62 4 SAFETY IN THE PIVOTAL PHASE 3 STUDIES ...............................................................62 4.1 Extent of Exposure .............................................................................................................62 4.2 Adverse Events ..................................................................................................................65 4.2.1 Overall Summary of TEAEs ........................................................................................65 4.2.2 Frequent TEAEs...........................................................................................................67 4.3 Serious Adverse Events .....................................................................................................69 4.4 Cardiac Safety ....................................................................................................................70 4.5 Liver Safety ........................................................................................................................75 4.6 Mortality ............................................................................................................................75 4.6.1 Mortality Across the Clinical Development Program .................................................75 4.6.1.1 Mortality in ABSSSI ..............................................................................................76 4.6.1.2 Mortality in CABP .................................................................................................77 4.6.1.3 Causes of Death in CABP ......................................................................................78 4.6.1.4 Mortality-Associated Safety Analyses ...................................................................79 4.6.1.5 Mortality in OPTIC - Discussion ...........................................................................80 4.7 Safety Conclusions.............................................................................................................82 5 BENEFIT RISK DISCUSSION .............................................................................................83 5.1 Benefits ..............................................................................................................................83
Load more

Recommended publications
  • Omadacycline (PTK796)
    Poster C1-609 Novartis Institutes for BioMedical Research, Inc. Omadacycline (PTK796) Mechanism of Action Studies by Using In Vitro Protein Synthesis 4560 Horton Street Session 87 Emeryville, CA 94608 Phone: 510-923-2057, Fax: 510-923-5550 Inhibition Assay and Molecular Modeling Email: [email protected] A. RUZIN, S. MULLIN, P. PETRONE, L. WHITEHEAD and P. A. BRADFORD − Novartis Institutes for BioMedical Research, Cambridge, MA Figure 1. Structures of molecules used in this study. Computational Chemistry • In comparison with tetracycline (Figure 3A), additional C. Omadacycline predicted binding pose using Cresset B. Omadacycline interaction map. ABSTRACT favorable molecular interactions are made in the C1054/G1053 alignment to tetracycline. N N N N The Thermus thermophilus X-ray solution of tetracycline within ADE966 GUA 966 H2N H H H H H H HO HO the 30S subunit (accession code 1HNW) was used for generating binding area with the additional tertiary-amine-containing N N O O O O CYT1054 H P O HO H H P N Background H H CYT1195 OH H N N H N side-chains of both omadacycline and tygecycline. H OHOH O 2 2 N the modeling hypotheses. The ConQuest small molecule X-ray H N N O N N 2 Omadacylcine (OMC) is a novel aminomethylcycline anti- OH OH H URA OH O 1196 O O OH O OH O O OH O OH O O OH O OH database for ligand three dimensional atomic structures was also • Omadacycline has a secondary amine functionality capable of N N bacterial compound. The structural similarity between OMC and H H H O used in the preparation of ligand structures.
    [Show full text]
  • Structural Basis for Potent Inhibitory Activity of the Antibiotic Tigecycline During Protein Synthesis
    Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis Lasse Jennera,b,1, Agata L. Starostac,1, Daniel S. Terryd,e, Aleksandra Mikolajkac, Liudmila Filonavaa,b,f, Marat Yusupova,b, Scott C. Blanchardd, Daniel N. Wilsonc,g,2, and Gulnara Yusupovaa,b,2 aInstitut de Génétique et de Biologie Moléculaire et Cellulaire, Institut National de la Santé et de la Recherche Médicale U964, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7104, 67404 Illkirch, France; bUniversité de Strasbourg, F-67084 Strasbourg, France; cGene Center and Department for Biochemistry, University of Munich, 81377 Munich, Germany; dDepartment of Physiology and Biophysics, Weill Medical College of Cornell University, New York, NY 10065; eTri-Institutional Training Program in Computational Biology and Medicine, New York, NY 10065; fMax Planck Institute for Biophysical Chemistry, 37077 Göttingen, Germany; and gCenter for Integrated Protein Science Munich, University of Munich, 81377 Munich, Germany Edited by Rachel Green, Johns Hopkins University, Baltimore, MD, and approved January 17, 2013 (received for review September 28, 2012) + Here we present an X-ray crystallography structure of the clinically C1054 via a coordinated Mg2 ion (Fig. 1 D and E), as reported relevant tigecycline antibiotic bound to the 70S ribosome. Our previously for tetracycline (2). In addition, ring A of tigecycline + structural and biochemical analysis indicate that the enhanced coordinates a second Mg2 ion to facilitate an indirect interaction potency of tigecycline results from a stacking interaction with with the phosphate-backbone of G966 in h31 (Fig. 1 C–E). We also nucleobase C1054 within the decoding site of the ribosome.
    [Show full text]
  • Clinical Policy: Amikacin (Arikayce) Reference Number: CP.PHAR.401 Initial Approval Criteria A
    Title: Q1 2019 PDL Changes The following list of recommended Preferred Drug List (PDL) changes were reviewed and approved by the MHS Pharmacy & Therapeutics (P&T) Committee on January 16th, 2019. Table 1: Summary PDL Changes – Effective 3/1/2019 Drug Action Notes: Galafold Add to PDL with A. Fabry Disease (must meet all): PA 1. Diagnosis of Fabry disease; (Migalastat HCl) 2. Prescribed by or in consultation with a clinical geneticist; 3. Age ≥ 18 years; 4. Presence of at least one amenable GLA variant (mutation), as confirmed by one of the following resources (a, b, or c): a. Galafold Prescribing Information brochure (package insert; Section 12, Table 2); b. Amicus Fabry GLA Gene Variant Search Tool:; c. Amicus Medical Information 5. Galafold is not prescribed concurrently with Fabrazyme; 6. Dose does not exceed 123 mg (1 capsule) every other day. Delstrigo Add to PDL with Trial of Symfi for treatment naïve members. ST (Doravirine- Lamivudine- Tenofovir DF) New Drug Specific PA Criteria: Full Medical Necessity Crieria Posted at: https://www.mhsindiana.com/providers/resources/clinical-payment-policies.html Clinical Policy: Amikacin (Arikayce) Reference Number: CP.PHAR.401 Initial Approval Criteria A. Mycobacterium Avium Complex (MAC) (must meet all): 1. Diagnosis of MAC; 2. Prescribed by or in consultation with an infectious disease specialist or pulmonologist; 3. Age ≥ 18 years; 4. Failure, as evidenced by positive sputum culture, of at least a 6-month trial of a multidrug background regimen therapy at up to maximally indicated doses (see Appendix B), unless contraindicated or clinically significant adverse effects are experienced; 5.
    [Show full text]
  • New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics
    pharmaceuticals Review New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics Nicola Principi 1, Alberto Argentiero 2, Cosimo Neglia 2, Andrea Gramegna 3,4 and Susanna Esposito 2,* 1 Università degli Studi di Milano, 20122 Milan, Italy; [email protected] 2 Pediatric Clinic, Pietro Barilla Children’s Hospital, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy; [email protected] (A.A.); [email protected] (C.N.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, 20122 Milan, Italy; [email protected] 4 Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy * Correspondence: [email protected]; Tel.: +39-052-190-3524 Received: 29 September 2020; Accepted: 19 October 2020; Published: 23 October 2020 Abstract: Acute bacterial skin and soft tissue infections (aSSTIs) are a large group of diseases that can involve exclusively the skin or also the underlying subcutaneous tissues, fascia, or muscles. Despite differences in the localization and severity, all these diseases are due mainly to Gram-positive bacteria, especially Staphylococcus aureus and Streptococcus pyogenes. aSSTI incidence increased considerably in the early years of this century due to the emergence and diffusion of community-acquired methicillin-resistant S. aureus (CA-MRSA). Despite the availability of antibiotics effective against CA-MRSA, problems of resistance to these drugs and risks of significant adverse events have emerged. In this paper, the present knowledge on the potential role new antibiotics for the treatment of pediatric aSSTIs is discussed. The most recent molecules that have been licensed for the treatment of aSSTIs include ozenoxacin (OZ), ceftaroline fosamil (CF), dalbavancin (DA), oritavancin (OR), tedizolid (TD), delafloxacin (DL), and omadacycline (OM).
    [Show full text]
  • Preliminary, Real-World, Multicenter Experience with Omadacycline for Mycobacterium Abscessus Infections
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2021 Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections Taylor Morrisette Sara Alosaimy Julie V. Philley Carly Wadle Catessa Howard See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Authors Taylor Morrisette, Sara Alosaimy, Julie V. Philley, Carly Wadle, Catessa Howard, Andrew J. Webb, Michael P. Veve, Melissa L. Barger, Jeannette Bouchard, Tristan W. Gore, Abdalhamid M. Lagnf, Iman Ansari, Carlos Mejia-Chew, Keira A. Cohen, and Michael J. Rybak applyparastyle “fig//caption/p[1]” parastyle “FigCapt” Open Forum Infectious Diseases BRIEF REPORT Preliminary, Real-world, Multicenter an important therapeutic for NTM treatment, if susceptible, and also available in an oral formulation) and prolonged treat- Experience With Omadacycline for ment durations that are typically expensive [2]. Furthermore, Mycobacterium abscessus Infections a lack of clinical trials and minimally effective oral therapies Taylor Morrisette,1 Sara Alosaimy,1 Julie V. Philley,2 Carly Wadle,2 Catessa Howard,3 lead to variations in how patients are treated and further com- Downloaded from https://academic.oup.com/ofid/article/8/2/ofab002/6067597 by Washington University in St. Louis user on 05 March 2021 Andrew J. Webb,4,5 Michael P. Veve,6,7 Melissa L. Barger,8 Jeannette Bouchard,9 promise patient satisfaction, respectively [3]. It is crucial that 9 1 1 10 Tristan W. Gore, Abdalhamid M. Lagnf., Iman Ansari, Carlos Mejia-Chew, novel antibiotics with optimal oral bioavailability, minimal Keira A. Cohen,11 and Michael J. Rybak1,12,13 adverse effects (AEs), and effectiveness against all subspecies 1Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA, 2Division of M.
    [Show full text]
  • Antibiotics Currently in Clinical Development
    A data table from Feb 2018 Antibiotics Currently in Global Clinical Development Note: This data visualization was updated in December 2017 with new data. As of September 2017, approximately 48 new antibiotics1 with the potential to treat serious bacterial infections are in clinical development. The success rate for clinical drug development is low; historical data show that, generally, only 1 in 5 infectious disease products that enter human testing (phase 1 clinical trials) will be approved for patients.* Below is a snapshot of the current antibiotic pipeline, based on publicly available information and informed by external experts. It will be updated periodically, as products advance or are known to drop out of development. Because this list is updated periodically, endnote numbers may not be sequential. In September 2017, the antibiotics pipeline was expanded to include products in development globally. Please contact [email protected] with additions or updates. Expected activity Expected activity against CDC Development against resistant Drug name Company Drug class Target urgent or WHO Potential indication(s)?5 phase2 Gram-negative critical threat ESKAPE pathogens?3 pathogen?4 Approved for: Acute bacterial skin and skin structure infections; other potential Baxdela Approved June 19, Melinta Bacterial type II Fluoroquinolone Possibly No indications: community-acquired bacterial (delafloxacin) 2017 (U.S. FDA) Therapeutics Inc. topoisomerase pneumonia and complicated urinary tract infections6 Approved for: Complicated urinary Rempex tract infections including pyelonephritis; Vabomere Pharmaceuticals β-lactam (carbapenem) other potential indications: complicated Approved Aug. 30, (Meropenem + Inc. (wholly owned + β-lactamase inhibitor PBP; β-lactamase Yes Yes (CRE) intra-abdominal infections, hospital- 2017 (U.S.
    [Show full text]
  • Visão De Futuro Para Produção De Antibióticos: Tendências De Pesquisa, Desenvolvimento E Inovação
    UNIVERSIDADE FEDERAL DO RIO DE JANEIRO CRISTINA D’URSO DE SOUZA MENDES SANTOS VISÃO DE FUTURO PARA PRODUÇÃO DE ANTIBIÓTICOS: TENDÊNCIAS DE PESQUISA, DESENVOLVIMENTO E INOVAÇÃO Rio de Janeiro EQ/UFRJ 2014 CRISTINA D ’U RSO DE SOUZA MENDES SANTOS VISÃO DE FUTURO PARA A PRODUÇÃO DE ANTIBIÓTICOS: TENDÊNCIAS DE PESQUISA, DESENVOLVIMENTO E INOVAÇÃO Tese de Doutorado apresentada ao Programa de Pós-Graduação em Tecnologia de Processos Químicos e Bioquímicos, Escola de Química, Universidade Federal do Rio de Janeiro, como requisito parcial à obtenção do título de Doutor em Ciências, D.Sc. Orientadora: Profa. Adelaide Maria de Souza Antunes, D.Sc. Rio de Janeiro 2014 Santos, Cristina d’Urso de Souza Mendes. Visão de futuro para produção de antibióticos: tendências de pesquisa, desenvolvimento e inovação / Cristina d’Urso de Souza Mendes Santos. - Rio de Janeiro, 2014. 216 f.: il.; 29,7 cm. Tese (Doutorado em Ciências) – Universidade Federal do Rio de Janeiro, Escola de Química, Programa de Pós-Graduação em Tecnologia de Processos Químicos e Bioquímicos, Rio de Janeiro, 2014. Orientadora: Adelaide Maria de Souza Antunes. 1. Antibióticos. 2. P&D na Indústria Farmacêutica. 3. Prospecção Tecnológica. 4. Patentes. I. Antunes, Adelaide Maria de Souza. II. Universidade Federal do Rio de Janeiro. Escola de Química. III. Visão de futuro para a produção de antibióticos: tendências de pesquisa, desenvolvimento e inovação. iv v Dedico esta tese à minha mãe querida e amada, que está no céu comemorando esta vitória, que é mais dela do que minha. Dedico também à minha filhinha Malu que sem entender foi a minha maior motivação para concluir esta tese.
    [Show full text]
  • Activity of Omadacycline When Tested Against Gram-Positive Bacteria Isolated from Robert K
    IDWEEK 2016 Activity of Omadacycline when Tested against Gram-Positive Bacteria Isolated from Robert K. Flamm, PhD JMI Laboratories Patients in the USA During 2015 as Part of a Global Surveillance Program 335 Beaver Kreek Centre 1827 North Liberty, Iowa 52317 Phone: (319) 665-3370 New Orleans, LA RK FLAMM, RE MENDES, MD HUBAND, HS SADER [email protected] October 26 - 30 JMI Laboratories, North Liberty, Iowa, USA • Enterococcus faecalis (n=636) and E. faecium (n=241): Table 2. Activity of omadacycline and comparator agents when tested against 5,082 Gram- positive isolates collected during 2015 in the USA. Figure 1. Omadacycline 2015 surveillance isolate total (%) by USA Census Region Amended Abstract Methods o Omadacycline was highly active against both E. faecalis and E. faecium isolates with MIC50/90 CLSIa EUCASTa values of 0.06/0.12 µg/ml. Against vancomycin-non-susceptible E. faecium, omadacycline was Organism MIC MIC Range 50 90 %S %I %R %S %I %R Background: Omadacycline (OMC) is a broad spectrum Sampling sites and Organisms: A total of 5,102 non-duplicate, single-patient Gram- slightly less active with an MIC value of 0.25 µg/ml (Table 1). Staphylococcus aureus (2,148) 90 Omadacycline 0.12 0.12 0.015 — 2 - - - - - - New England (n=481) aminomethylcycline in late stage clinical development for the treatment positive clinical isolates that originated from the SENTRY surveillance network in b 11% 9% o Tigecycline was also very active against both E. faecalis (99.8% susceptible) and E. faecium Tigecycline 0.06 0.12 ≤0.015 — 0.5 100.0 - - 100.0 - 0.0 Mid-Atlantic (n=562) of acute bacterial skin and skin structure infections and community- North America (USA) during 2015 were received by JMI Laboratories.
    [Show full text]
  • NUZYRA (Omadacycline)
    HIGHLIGHTS OF PRESCRIBING INFORMATION Tablets: 150 mg omadacycline (equivalent to 196 mg omadacycline These highlights do not include all the information needed to use tosylate) (3.2) NUZYRATM safely and effectively. See full prescribing information for NUZYRA. -------------------------------CONTRAINDICATIONS------------------------------ Known hypersensitivity to omadacycline, tetracycline-class NUZYRA (omadacycline) for injection, for intravenous use antibacterial drugs or any of the excipients in NUZYRA (4) NUZYRA (omadacycline) tablets, for oral use Initial U.S. Approval: 2018 ------------------------WARNINGS AND PRECAUTIONS----------------------- Mortality Imbalance in Patients with CABP: In the CABP trial, -----------------------------INDICATIONS AND USAGE-------------------------- mortality rate of 2% was observed in NUZYRA-treated patients NUZYRA is a tetracycline class antibacterial indicated for the treatment compared to 1% in moxifloxacin-treated patients. The cause of the of adult patients with the following infections caused by susceptible mortality imbalance has not been established. Closely monitor microorganisms (1): clinical response to therapy in CABP patients, particularly in those at higher risk for mortality. (5.1, 6.1) Community-acquired bacterial pneumonia (CABP) (1.1) Tooth Discoloration and Enamel Hypoplasia: The use of NUZYRA Acute bacterial skin and skin structure infections (ABSSSI) (1.2) during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration To reduce the development of drug-resistant bacteria and maintain the of the teeth (yellow-gray-brown) and enamel hypoplasia. (5.2, 8.1, effectiveness of NUZYRA and other antibacterial drugs, NUZYRA 8.4) should be used only to treat or prevent infections that are proven or Inhibition of Bone Growth: The use of NUZYRA during the second strongly suspected to be caused by susceptible bacteria.
    [Show full text]
  • Minimal Inhibitory Concentration of Omadacycline and Doxycycline Against Bacterial Isolates with Known Tetracycline Resistance Determinants
    Diagnostic Microbiology and Infectious Disease 94 (2019) 78–80 Contents lists available at ScienceDirect Diagnostic Microbiology and Infectious Disease journal homepage: www.elsevier.com/locate/diagmicrobio Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants Ad C. Fluit ⁎, Sjoukje van Gorkum, Judith Vlooswijk Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands article info abstract Article history: Omadacycline is an aminomethylcycline derived from the tetracycline class. The minimum inhibitory concentra- Received 12 September 2018 tion of 115 Enterobacteriaceae and Staphylococcus aureus isolates with known tetracycline resistance determi- Received in revised form 9 November 2018 nants against omadacycline and doxycycline was determined by broth microdilution. Omadacycline is, on a Accepted 16 November 2018 weight basis, more active than doxycycline for nearly all isolates, and differences in activity correlated with or- Available online 29 November 2018 ganism rather than resistance mechanism. Keywords: © 2018 Elsevier Inc. All rights reserved. MIC Omadacycline Doxycycline Resistance Antibiotic resistance is recognized as an increasing problem as thera- and is susceptible to tetracycline resistance mechanisms. The isolates peutic options for serious infections become more limited. The urgent were selected based on results obtained by specific PCRs for tetracycline need for new antibiotics is widely recognized.
    [Show full text]
  • What's Hot in Infectious Diseases
    What’s Hot in Infectious Diseases - Clinical Science? Stan Deresinski MD FACP FIDSA Clinical Professor of Medicine Stanford University No Disclosures 1884 Pakistan: Salmonella enterica serovar typhi MDR - XDR • November 2016, Hyderabad Pakistan Integrated transposon • Appearance of a H58 haplotype strain encoding amp, chloro, resistant to antibiotics of 5 classes T/S resistance + gyrA • Resulted from acquisition of single mutation chromosomal and plasmid mediated mechanisms by dominant H58 haplotype IncY plasmid* • Plasmid carrying qnrS, blaCTX-M-15 acquired from E. coli blaCTXM-15 • Susceptible only to imipenem, qnrS azithromycin MDR – chloramphenicolR, T/SR, ampicillinR XDR – MDR plus ceftriaxoneR, fluoroquinoloneR mBio. January/February 2018 Volume 9 Issue 1 e00105-18 XDR Typhoid – Pakistan & Beyond • Rapid increase in case numbers with spread to Karachi WHO prequalified use of conjugate vaccine (Typbar-TCV®) – single dose, immunogenic in children >6 months of age • At least 3 travelers returned with infection - one to UK, 2 to US July 11, 2018 “Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs” https://endpts.com/novartis-joins-the-big-pharma-exodus-out-of-antibiotics-dumping-research-cutting-140-and-out-licensing-programs/ https://gizmodo.com/novartis-becomes-the-latest-pharma-company-to-give-up-o-1827524081 Selected Antibacterials Expected to Be Submitted to the FDA for Approval by Mid-2019 https://cdn2.hubspot.net/hubfs/498900/Jul2018_DrugPriceForecast_Media_FINAL.pdf Cefiderocol • Siderophore cephalosporin • Panel (N=315) of carbapenemase- producing MDR GNR – MIC <4 mcg/ml: • Enterobacteriaeceae – 87.5% • P. aeruginosa - 100% • A. baumanii - 89% • Activity by carbapenemase type: • A – 91.8% B - 74.8% D – 98.0% IDWeek 2017.
    [Show full text]
  • The Novel Aminomethylcycline Omadacycline Has High Specificity
    antibiotics Article The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome Corina G. Heidrich 1, Sanya Mitova 1, Andreas Schedlbauer 2, Sean R. Connell 2,3, Paola Fucini 2,3, Judith N. Steenbergen 4 and Christian Berens 1,5,* 1 Microbiology, Department of Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany; [email protected] (C.G.H.); [email protected] (S.M.) 2 Structural Biology Unit, CIC bioGUNE, 48160 Derio, Bizkaia, Spain; [email protected] (A.S.); [email protected] (S.R.C.); [email protected] (P.F.) 3 IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain 4 Paratek Pharmaceuticals Inc., King of Prussia, PA 19406, USA; [email protected] 5 Institute of Molecular Pathogenesis, Friedrich-Loeffler-Institut, 07743 Jena, Germany * Correspondence: christian.berens@fli.de; Tel.: +49-3641-804-2500 Academic Editor: Claudio O. Gualerzi Received: 27 March 2016; Accepted: 12 September 2016; Published: 22 September 2016 Abstract: Omadacycline is an aminomethylcycline antibiotic with potent activity against many Gram-positive and Gram-negative pathogens, including strains carrying the major efflux and ribosome protection resistance determinants. This makes it a promising candidate for therapy of severe infectious diseases. Omadacycline inhibits bacterial protein biosynthesis and competes with tetracycline for binding to the ribosome. Its interactions with the 70S ribosome were, therefore, analyzed in great detail and compared with tigecycline and tetracycline. All three antibiotics are inhibited by mutations in the 16S rRNA that mediate resistance to tetracycline in Brachyspira hyodysenteriae, Helicobacter pylori, Mycoplasma hominis, and Propionibacterium acnes. Chemical probing with dimethyl sulfate and Fenton cleavage with iron(II)-complexes of the tetracycline derivatives revealed that each antibiotic interacts in an idiosyncratic manner with the ribosome.
    [Show full text]